Project Details
Description
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/18 → 1/22/23 |
Funding
- OX2 THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.